| JNCE Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the JNCE shares outstanding history going back to 1/27/2017:
Also see: JNCE Market Cap History JNCE YTD Return |
JNCE Shares Outstanding History — Jounce Therapeutics Share Count Over Time
As of 3/7/2023 Jounce Therapeutics has 52.14 million JNCE shares outstanding. Investors often track the JNCE shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows JNCE share count trends over time, with 27 historical shares outstanding datapoints presented, dating back to 1/27/2017.
| JNCE Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JNCE Historical Shares Outstanding: +9.37% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| JNCE Stock Price Chart |
| About Jounce Therapeutics Inc |
| Jounce Therapeutics is a clinical-stage immunotherapy company focuses on the treatment of cancer by developing therapies that enable the immune system to attack tumors. Co.'s product candidates include: JTX-8064, an antibody that binds to Leukocyte Immunoglobulin Like Receptor B2; Vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells commonly found in several solid tumors; Pimivalimab, a clinical-stage anti-PD-1 antibody for potential use in combination with its product candidates; and GS-1811, a monoclonal antibody that depletes T regulatory cells in the tumor microenvironment. We show 27 historical shares outstanding datapoints in our coverage of JNCE's shares outstanding history. Understanding the changing numbers of JNCE shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like JNCE versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching JNCE by allowing them to research JNCE shares outstanding history as well as any other stock in our coverage universe. |
| JNCE Current Stock Quote |
Quotes delayed 20 minutes  Free JNCE Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| JNCE Share Performance |
| Shares Outstanding Peers |
| Jounce Therapeutics (JNCE) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
JNJ Shares Outstanding History JNP Shares Outstanding History JSPR Shares Outstanding History JUNS Shares Outstanding History JUPW Shares Outstanding History KA Shares Outstanding History KA Shares Outstanding History KALA Shares Outstanding History KALV Shares Outstanding History KDMN Shares Outstanding History More Healthcare companies » |
JNCE Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
